Calò Federica, Onorato Lorenzo, Pisaturo Mariantonietta, Pinto Antonio, Alessio Loredana, Monari Caterina, Minichini Carmine, Arcamone Manuela, Di Fraia Alessandra, Atripaldi Luigi, Tiberio Claudia, Coppola Nicola
Department of Mental Health and Public Medicine-Infectious Diseases Unit, University of Campania Luigi Vanvitelli, 80131 Naples, Italy.
Hematology-Oncology and Stem Cell Transplantation Unit, Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, 80131 Naples, Italy.
Vaccines (Basel). 2022 Jun 26;10(7):1021. doi: 10.3390/vaccines10071021.
Few data are available regarding the effectiveness of anti-SARS-CoV-2 vaccine in immunocompromised patients. Vaccination may have a suboptimal efficacy in this population, in particular if patients are exposed to anti-B-cell therapy. We report the virological and clinical characteristics of a patient with follicle center lymphoma under bimonthly maintenance therapy with obinutuzumab, an anti-CD20 monoclonal antibody. Despite three doses of BNT162b2 vaccine, the patient was infected by the SARS-CoV-2 Omicron variant. After an initial period of clinical and molecular remission due to early therapy with sotrovimab, the patient experienced a fatal relapse sustained by the same viral strain.
关于抗SARS-CoV-2疫苗在免疫功能低下患者中的有效性，可用数据很少。在这一人群中，疫苗接种可能效果欠佳，尤其是当患者接受抗B细胞治疗时。我们报告了一名滤泡中心淋巴瘤患者的病毒学和临床特征，该患者每两个月接受一次抗CD20单克隆抗体奥妥珠单抗的维持治疗。尽管接种了三剂BNT162b2疫苗，该患者仍感染了SARS-CoV-2奥密克戎变种。在接受索托维单抗早期治疗后，患者经历了一段临床和分子缓解期，但随后又被同一病毒株导致致命复发。
